Status:
RECRUITING
Mucopolysaccharidosis I (MPS I) Registry
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Mucopolysaccharidosis I (MPS I)
Eligibility:
All Genders
Brief Summary
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to...
Detailed Description
The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: * In Asia-Pacific - Vivian Liu, +65-6431-25...
Eligibility Criteria
Inclusion
- All patients with a confirmed diagnosis of MPS I are eligible for inclusion. Confirmed diagnosis is defined as: A. documented biochemical evidence of a deficiency in alpha (a)-L-iduronidase enzyme activity and/or B. mutation(s) in the gene coding for a-L-iduronidase, or measurable clinical signs and symptoms of MPS I
- For all patients there should be a completed patient authorization form
Exclusion
- No exclusion criteria for participation in the MPS I Registry. NOTE: Registry participation does not exclude participation in other clinical studies.
Key Trial Info
Start Date :
November 20 2003
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2034
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00144794
Start Date
November 20 2003
End Date
January 31 2034
Last Update
October 31 2025
Active Locations (180)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Children's Hospital- Site Number : 840003
Phoenix, Arizona, United States, 85013
2
Arkansas Childrens Hospital- Site Number : 840109
Little Rock, Arkansas, United States, 72202
3
Southern California Permanente Medical Group- Site Number : 840108
Los Angeles, California, United States, 90027
4
USC Health Sciences Center Dept of Genetics- Site Number : 840082
Los Angeles, California, United States, 90033